

Application Number 10/617,619
January 11, 2005

6455.200-US
Page 7 of 8

REMARKS

Claim 26 is hereby cancelled, without prejudice or disclaimer. Claim 22 is amended to comply with the sequence rules. An amended sequence listing is filed separately but concurrently. No new matter is added by either amendment. The amendment does not impact on the scope of the claims. New claim 29 is directed to one of the species set forth in the Office Action. No new matter is added.

Claims 1-25 and 27-29 are pending; claims 1, 25, and 27 are the only independent claims; claims 27 and 28 are currently withdrawn.

In response to the restriction requirement set forth in the Office Action of December 15, 2004, Applicants hereby elect Group I (associated in the Office Action with claims 1-26) for further prosecution in the subject application. Original (i.e., unamended) claims 27 and 28 are accordingly withdrawn, but not cancelled, as rejoinder of these claims may be warranted upon allowance of similar composition claims.

The Office Action further sets forth three species selection requirements that pertain to Group I and one species selection requirement that pertains to Group II (the Group II species election requirement is believed to be moot in view of the election of Group I). Each species selection requirement is addressed separately here.

First, the Office Action requires selection of a compound that catalytically inactivates FVIIa. Applicants hereby select Phe-Phe-Arg chloromethyl ketone as the species for this aspect of the currently claims for prosecution on the merits, *in the event no generic claim is held allowable*. New claim 29 is directly "readable on" a compound according to this species. All other pending and unwithdrawn claims are generic with respect to this element of the claims.

Second, the Office Action requires selection of an immunostimulatory effector used in the fusion construct. Applicants hereby select fusion proteins wherein

Application Number 10/617,619
January 11, 2005

6455,200-US
Page 8 of 8

element "C" of the compound comprises an Fc domain of an immunoglobulin molecule or fragment thereof as the species for this aspect of the currently claims for prosecution on the merits, *in the event no generic claim is held allowable*. Of the pending and unwithdrawn claims, currently, claims 10, 16, and 17 are directly "readable on" such a compound. Claims 1-6, 8, 11-15, 18-25, and 29 are generic with respect to this aspect of the claims. Claims 7 and 9 are directed to distinct species with respect to this type of claim element.

Third and finally, the Office Action requires selection of a linker moiety in the fusion construct for prosecution *in the event no generic claim is held allowable*. Applicants hereby select the species of compounds wherein "LM" comprises the amino acid sequence (Gly-Gly-Gly-Gly-Ser (SEQ ID NO:14))_n, wherein n is any integer from 1 to 10, in response to this species selection requirement. Claim 22 is directly readable on this species. Claims 1-21, 25, and 29 are generic with respect to this aspect of the claims. Claims 23 and 24 are directed to distinct species.

It is respectfully submitted that the elected claims are in condition for allowance. Early action to that end is respectfully requested. The Commissioner is hereby authorized to charge any fees in connection with this application and to credit any overpayments to Deposit Account No. 14-1447. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution and allowance of this application, the Examiner is hereby invited to call the undersigned attorney.

Respectfully submitted,

Date: January 11, 2005

/Len S. Smith, #43139/
Len S. Smith, Reg. No. 43,139
Novo Nordisk, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Please Use the following customer number for all correspondence regarding this application.
23650

PATENT TRADEMARK OFFICE